Glyoka-M1 Forte Tablet PR is a fixed-dose combination medication containing Glimepiride 1mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to reduced blood glucose levels. This combination offers complementary mechanisms of action that effectively lower fasting and postprandial blood glucose. Glyoka-M1 Forte Tablet PR is intended for patients inadequately controlled on diet and exercise alone or those requiring additional glycemic control beyond monotherapy. The prolonged-release formulation ensures a steady plasma concentration, minimizing gastrointestinal side effects commonly associated with metformin immediate-release formulations. It is essential to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with metformin. Caution is advised in patients with hepatic impairment, cardiovascular disease, or conditions predisposing to hypoxia. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and adjust dosage accordingly. Glyoka-M1 Forte Tablet PR should be used as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modifications.

Dosage & How to Use